Search Results
86 Results Found for “precision medicine”
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...
From adjuvant immunotherapy to microbiome-driven precision medicine, the biggest renal cell carcinoma abstracts presented at ASCO 2026 highlight where the field is heading next, and what may change first. In this round-up, we discuss the key data from four of the meeting’s most important studies, from investigational to late-phase: RAMPART, KEYNOTE-564, CaboNivo in patients with nccRCC and microbiome-based predictive biomarker development in mRCC.
Landmark abstracts across localized and advanced prostate cancer presented at ASCO 2026 addressed treatment intensification, biomarker-driven therapy, radiotherapy modality comparisons, and novel radioligand strategies. In this piece we examine four studies that reflect important shifts in prostate cancer management, influencing both near-term treatment pathways and future: PROTEUS, TALAPRO-3, COMPPARE and ProstACT Global.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
Congress coverage | This May, experts from around the world gathered in Glasgow, Scotland for the the 7th SIOP Europe Annual Meeting. This year celebrated the importance of collaboration, bringing together the diverse stakeholders involved in facing children and adolescents with cancer, and ensuring all voices were heard. The Annual Meeting was held in partnership with CCI Europe, ensuring the representation and participation of childhood cancer parents and survivors.
Professor Pamela Kearns discusses the key points from her Plenary presentation on how the ITCC is expanding access to innovative therapies, harnessing precision data and reshaping Europe’s paediatric oncology clinical trial landscape. “We want to bring innovation directly to ...
At SIOPE 2026, discussions around early phase clinical development highlighted both the scientific advances and structural challenges shaping modern paediatric oncology. Prof Cornelis Van Tilburg is closely involved in both areas through his leadership of the clinical trials unit and multiple investigator-initiated studies in paediatric neuro-oncology. In this interview, he discusses the barriers affecting European early phase research, evolving paediatric trial methodologies, and the importance of international collaboration in precision oncology.
The 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona brought together over 9,400 participants, marking a major milestone. The meeting highlighted major advances in oncologic imaging and theranostics, with a strong emphasis on precision medicine and combination treatment strategies. Across plenary sessions, debates, and late-breaking discussions, the meeting underscored how nuclear medicine is increasingly central to cancer diagnosis, treatment selection, and therapeutic delivery.
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1Â Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
In this Future Leaders interview, Dr Gómez Rivas discusses the mentors who shaped his career, the values that sustain a life in surgery and research, and the importance of mentorship, teamwork and resilience for the next generation of urologists.
In this touchONCOLOGY Future Leaders 2026 interview, Dr Lenz reflects on the mentorship that shaped his commitment to oncology, the role of research in exposing inequities in cancer care, and why ensuring equitable access to innovation will define the future of the field.
In this Future Leaders interview, Dr Soniya Dulal discusses the global mentors who shaped her career, the importance of building sustainable oncology systems in Nepal and how precision medicine, palliative care and international collaboration can improve patient outcomes in resource-limited settings.
At EAU26, Dr Juan Gómez Rivas reflected on a period of rapid transformation in the field. Across mentorship, technology and precision medicine, Dr Gómez Rivas believes the field is entering a new era. For urologists, he says, the message is simple: embrace innovation, collaborate widely and keep patients at the centre of every advance.
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2Â Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3Â Currently, it has the ...
From breakthrough perioperative regimens to biomarker-driven precision therapy, ESMO 2025 unveiled practice-changing data in bladder cancer. Landmark trials like KEYNOTE-905, IMvigor011, and BladderPath are redefining standards across disease stages—offering new hope for cisplatin-ineligible patients, guiding adjuvant decisions through ctDNA, and streamlining diagnostics with MRI.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
